Skip to main content
For US Healthcare Professionals Only
Quick Links
Prescribing Information
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
Adverse Event Reporting
Report an Adverse Event or Product Complaint
Email
1-844-599-CARE (2273)
Connect With an MSL
Connect With Us
Main navigation
Home
Our Science
Overview
Publications
Clinical Pipeline
Opportunities for Investigators
Disease Education
Overview
Dermatology
Epilepsy
Rare Disease
Rheumatology
Podcasts
Independent Medical Education
Congress Materials
Medical Information
Overview
Submit Medical Inquiry
Slide Library
HCP Resources
Prescribing Information
Connect With an MSL
Connect With Us
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
Home
Congress Materials
American Academy of Neurology (AAN), 2025
Disruptive impacts of developmental and epileptic encephalopathies on patient and family life: a quality-of-life survey
Back to search results
Disruptive impacts of developmental and epileptic encephalopathies on patient and family life: a quality-of-life survey
View PDF
For US Healthcare Professionals Only
For US Healthcare Professionals Only